Review Article|Articles in Press

Primary Cardiac Involvement in Systemic Sclerosis

Best Approach to Diagnosis
Published:March 01, 2023DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Rheumatic Disease Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Smith V.
        • Scirè C.A.
        • Talarico R.
        • et al.
        Systemic sclerosis: state of the art on clinical practice guidelines, RMD Open. 2018; 4e000782
      1. Ross L, Prior D, Proudman S, et al. Defining primary systemic sclerosis heart involvement: a scoping literature review, Semin Arthritis Rheum, 48, 2019, 874–887.

        • Bulkley B.H.
        • Ridolfi R.L.
        • Salyer W.R.
        • et al.
        Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction.
        Circulation. 1976; 53: 483-490
        • D'Angelo W.A.
        • Fries J.F.
        • Masi A.T.
        • et al.
        Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls.
        Am J Med. 1969; 46: 428-440
        • Elhai M.
        • Meune C.
        • Boubaya M.
        • et al.
        Mapping and predicting mortality from systemic sclerosis.
        Ann Rheum Dis. 2017; 76: 1897-1905
        • Denton C.P.
        • Khanna D.
        Systemic sclerosis.
        Lancet. 2017; 390: 1685-1699
        • Roofeh D.
        • Khanna D.
        Management of systemic sclerosis: the first five years.
        Curr Opin Rheumatol. 2020; 32: 228-237
        • Weatherald J.
        • Montani D.
        • Jevnikar M.
        • et al.
        Screening for pulmonary arterial hypertension in systemic sclerosis.
        Eur Respir Rev. 2019; 28
        • Avouac J.
        • Airò P.
        • Meune C.
        • et al.
        Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies.
        J Rheumatol. 2010; 37: 2290-2298
        • Schattke S.
        • Knebel F.
        • Grohmann A.
        • et al.
        Early right ventricular systolic dysfunction in patients with systemic sclerosis without pulmonary hypertension: a Doppler Tissue and Speckle Tracking echocardiography study.
        Cardiovasc Ultrasound. 2010; 8: 3
        • Bruni C.
        • Ross L.
        Cardiac involvement in systemic sclerosis: getting to the heart of the matter.
        Best Pract Res Clin Rheumatol. 2021; 35: 101668
        • Ferreira V.M.
        • Piechnik S.K.
        CMR parametric mapping as a tool for myocardial tissue characterization.
        Korean Circ J. 2020; 50: 658-676
      2. Besenyi Z., Ágoston G., Hemelein R., et al., Detection of myocardial inflammation by 18F-FDG-PET/CT in patients with systemic sclerosis without cardiac symptoms: a pilot study, Clin Exp Rheumatol, 37 (Suppl 119), 2019, 88–96.

        • Krumm P.
        • Mueller K.A.L.
        • Klingel K.
        • et al.
        Cardiovascular magnetic resonance patterns of biopsy proven cardiac involvement in systemic sclerosis.
        J Cardiovasc Magn Reson. 2017; 18: 70
        • Liangos O.
        • Neure L.
        • Kühl U.
        • et al.
        The possible role of myocardial biopsy in systemic sclerosis.
        Rheumatology. 2000; 39: 674-679
        • Mueller K.A.
        • Mueller I.I.
        • Eppler D.
        • et al.
        Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy.
        PLoS One. 2015; 10e0126707
        • Cooper Jr., L.T.
        N Engl J Med. 2009; 360: 1526-1538
        • Pucci A.
        • Aimo A.
        • Musetti V.
        • et al.
        Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis.
        J Am Heart Assoc. 2021; 10: e020358
        • Soong T.R.
        • Barouch L.A.
        • Champion H.C.
        • et al.
        New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases.
        Hum Pathol. 2007; 38: 1858-1863
        • Bissell L.A.
        • Anderson M.
        • Burgess M.
        • et al.
        Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis.
        Rheumatology. 2017; 56: 912-921
        • Bisignani A.
        • De Bonis S.
        • Mancuso L.
        • et al.
        Implantable loop recorder in clinical practice.
        J Arrhythm. 2019; 35: 25-32
        • Hung G.
        • Mercurio V.
        • Hsu S.
        • et al.
        Progress in understanding, diagnosing, and managing cardiac complications of systemic sclerosis.
        Curr Rheumatol Rep. 2019; 21: 68
        • Bissell L.A.
        • Dumitru R.B.
        • Erhayiem B.
        • et al.
        Incidental significant arrhythmia in scleroderma associates with cardiac magnetic resonance measure of fibrosis and hs-TnI and NT-proBNP.
        Rheumatology. 2019; 58: 1221-1226
        • Bernardo P.
        • Conforti M.L.
        • Bellando-Randone S.
        • et al.
        Implantable cardioverter defibrillator prevents sudden cardiac death in systemic sclerosis.
        J Rheumatol. 2011; 38: 1617-1621
        • Allanore Y.
        • Komocsi A.
        • Vettori S.
        • et al.
        N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis.
        Int J Cardiol. 2016; 223: 385-389
      3. Bosello S., De Luca G., Berardi G., et al., Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: a prospective study, Eur J Intern Med, 60, 2019, 46–53.

        • Fraiser L.H.
        • Kanekal S.
        • Kehrer J.P.
        Cyclophosphamide toxicity. Characterising and avoiding the problem.
        Drugs. 1991; 42: 781-795
        • Shah R.R.
        • Morganroth J.
        Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk/benefit.
        Drug Saf. 2015; 38: 693-710
        • Lescoat A.
        • Lelong M.
        • Jeljeli M.
        • et al.
        Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
        Biochem Pharmacol. 2020; 178: 114103
        • Kotyla P.J.
        • Islam M.A.
        • Engelmann M.
        Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
        Int J Mol Sci. 2020; 21
        • Farge D.
        • Burt R.K.
        • Oliveira M.C.
        • et al.
        Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners.
        Bone Marrow Transplant. 2017; 52: 1495-1503